Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Stopping NNRTIs in drug-resistant patients does not alter viral loads or CD4 cell counts

Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTIs) from the antiretroviral drug combination of patients with resistance to this drug class does not lead to viral

Published
28 June 2004
By
Christopher Gadd
The male genital tract is not a sanctuary site for HIV, argue Dutch researchers

A group of Dutch researchers have argued that the male genital tract is not an important site for the production of drug-resistant strains of HIV.

Published
28 June 2004
By
Christopher Gadd
Treatment failure due to drug resistance not a major cause of death

A Canadian study has found that treatment failure due to drug resistance did not significantly contribute to the mortality of people with HIV in British

Published
25 June 2004
By
Edwin J. Bernard
Infection with drug-resistant HIV has little effect on CD4 cell counts in the absence of therapy

Infection with a drug-resistant strain of HIV slightly accelerates CD4 T-cell decreases in the first year after seroconversion, but causes no difference in CD4 cell

Published
22 June 2004
By
Christopher Gadd
Study finds that 8% of newly diagnosed HIV patients in US have drug resistance

Resistance testing of individuals recently diagnosed with HIV before the initiation of HAART would identify a substantial number of patients with mutations causing resistance

Published
16 June 2004
By
Michael Carter
Genotype testing before treatment may identify patients susceptible to protease inhibitor resistance

The “primary” 90M mutation, which causes resistance to all protease inhibitors, is more likely to develop in people infected with HIV that already contains the

Published
02 June 2004
By
Christopher Gadd
Stopping nevirapine five days prior to nucleosides may avoid resistance

Stopping the nevirapine component of nevirapine-based HAART five days prior to the nucleoside backbone when stopping or interrupting treatment appears to be a “reasonable strategy”

Published
20 May 2004
By
Edwin J. Bernard
Offer baseline resistance tests to newly diagnosed UK immigrants, warn Brighton clinicians

The case of a Zimbabwean man who was treated with Combivir/efavirenz for his newly-diagnosed HIV infection in Brighton, but who was already resistant to nucleoside

Published
14 May 2004
By
Edwin J. Bernard
Prodrug of tenofovir works well in the presence of some NRTI resistance

Treatment-experienced individuals who have one or two thymidine analogue-associated resistance mutations still experience a significant reduction in HIV viral load if treated with tenofovir disoproxil

Published
02 May 2004
By
Michael Carter
First case of potential PI cross-resistance reported after lopinavir failure

Doctors in South Africa have reported the first case of Kaletra (lopinavir/ritonavir) failure in a protease inhibitor-naïve individual to be associated with a pattern of

Published
29 April 2004
By
Edwin J. Bernard

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.